期刊文献+

蔡鸿彦教授治疗社区获得性肺炎临床经验的研究

A Study on Clinical Experience of Professor Cai Hongyan in the Treatment of Community-acquired Pneumonia
下载PDF
导出
摘要 目的探究蔡鸿彦教授治疗社区获得性肺炎临床效果,积累社区获得性肺炎的经验。方法选取我院2017年3月至2018年12月收治的72例社区获得性肺炎患者作为研究对象,分为对照组和观察组,每组各36例。对照组采用盐酸左氧氟沙星治疗,观察组采用盐酸左氧氟沙星+麻柴苇茎汤治疗,比较两组临床疗效和治疗前后各项诊疗性指标。结果对照组临床治疗总有效率为77.78%(28/36),观察组临床治疗总有效率为94.44%(34/36),两组差异有统计学意义(P<0.05)。治疗前,对照组和观察组WBC、CRP、PCT水平差异无统计学意义(P>0.05);治疗后,观察组WBC、CRP、PCT水平均明显低于对照组,差异有统计学意义(P<0.05)。结论蔡鸿彦教授采用的麻柴苇茎汤治疗社区获得性肺炎疗效显著,可以改善患者的免疫功能,促进患者的健康恢复,值得临床广泛推广应用。 Objective To explore the clinical effects achieved by Professor Cai Hongyan in the treatment of community-acquired pneumonia and accordingly to accumulate the experience in community-acquired pneumonia treatment.Methods 72 patients suffering from community acquired pneumonia and admitted to Jilin Academy of Traditional Chinese Medicine from March 2017 to December 2018 were selected in the study.They were divided into a control group(n=36)and an observation group(n=36)evenly.Levofloxacin hydrochloride was applied to the control group while levofloxacin hydrochloride combined with decoction of Machai and Weijing,a treatment method adopted by Professor Cai Hongyan,was applied to the observation group.The clinical efficacy and the diagnostic indicators before and after the treatment were compared respectively.Results The overall response rate of clinical treatment in the control group was 77.78%(28/36)while it was 94.44%(34/36)in the observation group.The difference was statistically significant(P<0.05).Before treatment,the difference in WBC,CRP and PCT between the control group and the observation group was not statistically significant(P>0.05).After treatment,the WBC,CRP and PCT in the observation group were significantly lower than those in the control group,and the difference was statistically significant(P<0.05).Conclusion The treatment method adopted by Professor Cai Hongyan is significantly effective in the treatment of community-acquired pneumonia since it can improve patients’immunity and help them recover.Therefore,it is worthy of widespread application in clinical practice.
作者 席中原 李海燕 田雪秋 蔡鸿彦 XI Zhong-yuan;LI Hai-yan;TIAN Xue-qiu;CAI Hong-yan(Jilin Academy of Traditional Chinese Medicine,Changchun,Jilin 130021)
出处 《智慧健康》 2019年第15期33-35,共3页 Smart Healthcare
基金 2018年吉林省中医药科技项目(蔡鸿彦教授治疗社区获得性肺炎临床经验的研究2018100)
关键词 中西医结合 盐酸左氧氟沙星 麻柴苇茎汤 社区获得性肺炎 效果 Integrated traditional Chinese and Western medicine Levofloxacin hydrochloride Decoction of Machai and Weijing Community-acquired pneumonia Efficacy
  • 相关文献

参考文献6

二级参考文献68

  • 1段泾云.清热药的免疫药理研究[J].陕西中医,1994,15(3):135-136. 被引量:6
  • 2周耀端,黄益兰,赵文伟.泻白散加味治疗老年肺炎58例临床观察[J].湖南中医杂志,1996,12(5):14-15. 被引量:11
  • 3社区获得性肺炎诊断和治疗指南[J].中华结核和呼吸杂志,2006,29(10):651-655. 被引量:3041
  • 4社区获得性肺炎诊断和治疗指南(一)[J].全科医学临床与教育,2007,5(4):270-272. 被引量:38
  • 5Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Disea- ses Society of America/American Thoracic Society consensus guidelines on the management of community - acquired pneumonia in adults[ J ]. Clin Infect Dis, 2007, 44 (Suppl 2) :S27 -S72.
  • 6Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community - acquired pneumonia. Diagno- sis, assessment of severity, antimicrobial therapy, and prevention [J]. Am J Respir Cirt Care Med, 2001, 163(7) : 1730 -1754.
  • 7Wilson R, Maeklin - Doherty A. The use of moxifloxacin for acute exacerbations of chronic obstructive pulmonary disease and chronic bronchitis [ J ]. Expert Rev Respir Med, 2012, 6 ( 5 ) : 481 - 492.
  • 8Tones A, Garau J, Arris P, et al. Moxifloxacin monotherapy is ef- fective in hospitalized patients with community - acquired pneumo- nia : the MOTIV study - a randomized clinical trial [ J ]. Clin In- feet Dis, 2008, 46(10) : 1499 - 1509.
  • 9中医病证诊断疗效标准2012版(中华人民共和国中医药行业标准)[S].中国医药科技出版社,2012.
  • 10刘金丽,唐颖,李佳,等.c反应蛋白在社区获得性肺炎中的应用价值研究[J].实用心脑肺血管病杂志,2013,20(3):116.

共引文献86

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部